Mirae Asset Global Investments Co. Ltd. Sells 2,708 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Mirae Asset Global Investments Co. Ltd. lessened its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 6.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 36,875 shares of the biopharmaceutical company’s stock after selling 2,708 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Sage Therapeutics were worth $799,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in SAGE. CWM LLC grew its position in shares of Sage Therapeutics by 274.2% in the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 883 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Sage Therapeutics by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 748 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Sage Therapeutics by 17.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 1,375 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Sage Therapeutics in the 3rd quarter valued at about $219,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Sage Therapeutics in the 4th quarter valued at about $293,000. Institutional investors own 99.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “neutral” rating and issued a $28.00 price target on shares of Sage Therapeutics in a research report on Wednesday, April 17th. Scotiabank cut their target price on Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating on the stock in a research report on Thursday, April 18th. Bank of America lowered Sage Therapeutics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $24.00 to $14.00 in a research report on Wednesday, April 17th. TD Cowen cut their target price on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, April 18th. Finally, JPMorgan Chase & Co. upped their target price on Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, March 26th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $39.28.

Sage Therapeutics Stock Performance

Shares of NASDAQ:SAGE opened at $14.00 on Thursday. The business’s 50 day simple moving average is $18.99 and its two-hundred day simple moving average is $20.73. The firm has a market cap of $841.50 million, a P/E ratio of -1.55 and a beta of 0.86. Sage Therapeutics, Inc. has a 52-week low of $10.92 and a 52-week high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.73. The firm had revenue of $77.97 million during the quarter, compared to the consensus estimate of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company’s quarterly revenue was up 2621.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.47) earnings per share. On average, equities analysts forecast that Sage Therapeutics, Inc. will post -6.3 earnings per share for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.